Phosphorylation of the carboxyl-terminal domain (CTD) of RNA polymerase II is important for basal transcriptional processes in vivo and for cell viability. Several kinases, including certain cyclin-dependent kinases, can phosphorylate this substrate in vitro. It has been proposed that dierential CTD phosphorylation by dierent kinases may regulate distinct transcriptional processes. We have found that two of these kinases, cyclin C/CDK8 and cyclin H/CDK7/p36, can speci®-cally phosphorylate distinct residues in recombinant CTD substrates. This dierence in speci®city may be largely due to their varying ability to phosphorylate lysine-substituted heptapeptide repeats within the CTD, since they phosphorylate the same residue in CTD consensus heptapeptide repeats. Furthermore, this substrate speci®city is re¯ected in vivo where cyclin C/ CDK8 and cyclin H/CDK7/p36 can dierentially phosphorylate an endogenous RNA polymerase II substrate. Several small-molecule kinase inhibitors have dierent speci®cities for these related kinases, indicating that these enzymes have diverse active-site conformations. These results suggest that cyclin C/CDK8 and cyclin H/CDK7/p36 are physically distinct enzymes that may have unique roles in transcriptional regulation mediated by their phosphorylation of speci®c sites on RNA polymerase II.
Introduction
The carboxyl-terminal domain (CTD) of the largest subunit of eukaryotic RNA polymerase II is a highly conserved, unusual structure unique to this enzyme (Allison et al., 1985; Corden et al., 1985) . It consists of multiple, near-perfect tandem repeats of the sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser, and a minimum number of these CTD heptapeptide repeats is required for RNA polymerase II activity in vivo and for cell viability (Allison et al., 1988; Bartolomei et al., 1988; Nonet et al., 1987; Zehring et al., 1988) . RNA polymerase II becomes heavily phosphorylated during the course of transcription, and this phosphorylation mostly occurs on the CTD (Cadena and Dahmus, 1987; Dahmus, 1981) . Furthermore, mutational analysis has demonstrated that potential phosphorylation sites on the CTD are also essential in vivo (West and Corden, 1995) .
CTD phosphorylation appears to play multiple roles in transcriptional regulation (Corden, 1993; Dahmus, 1996; Shilatifard et al., 1997; Steinmetz, 1997) . Phosphorylation of the CTD is thought to be required for both promoter clearance and ecient elongation (Akoulitchev et al., 1995; Arias et al., 1991; Lee and Greenleaf, 1997; Marshall et al., 1996; O'Brien et al., 1994; Song, 1996; Yankulov et al., 1995) . Various experiments have suggested that CTD phosphorylation may be important for modulation of gene-speci®c transcription (Arias et al., 1991; O'Brien et al., 1994; Song, 1996) . Phosphorylation of the CTD in mitosis may be involved in general inhibition of transcription (Gebara et al., 1997) . It has recently been demonstrated that the hyperphosphorylated CTD physically and functionally interacts with proteins required for splicing and polyadenylation, suggesting that it may also coordinate transcription with mRNA processing (Bregman et al., 1995; Du and Warren, 1997; Kim et al., 1997; McCracken et al., 1997; Mortillaro et al., 1996; Steinmetz, 1997; .
Several kinases and phosphatases can modify the phosphorylation state of the CTD in vitro. One of the best-characterized CTD kinases is cyclin H/CDK7/p36, which, like its yeast homolog KIN28/CCL1, is a component of the general transcription factor TFIIH (Cismowski et al., 1995; Feaver et al., 1991 Feaver et al., , 1994 Lu et al., 1992; Roy et al., 1994; Serizawa et al., 1995; Shiekhattar et al., 1995) . Cyclin C/CDK8 can also phosphorylate the CTD and co-puri®es with a transcriptionally active RNA polymerase II holoenzyme (Maldonado et al., 1996; Rickert et al., 1996) . The homologs of cyclin C and CDK8 in Saccharomyces cerevisiae, SRB10 and SRB11, genetically interact with the CTD and also co-purify with an RNA polymerase II holoenzyme (Liao et al., 1995) . Other cyclin-dependent kinases are capable of phosphorylating the CTD in vitro, including cyclin B/ CDC2, cyclin T/CDK9, cyclin K and the yeast kinase CTDK-1 (Cisek and Corden, 1989; Lee and Greenleaf, 1989; Marshall and Price, 1995; Zhu et al., 1997; Edwards et al., 1998; Wei et al., 1998; Peng et al., 1998) . In addition, both MAP kinases (Bellier et al., 1997; Dubois et al., 1994b; Venetianer et al., 1995) and the tyrosine kinases c-Abl and Arg (Baskaran et al., 1997; 1993) can phosphorylate the CTD in vitro. CTD phosphatases have been puri®ed from both human and yeast cells, and CTD dephosphorylation may also be important for transcriptional regulation (Chambers and Dahmus, 1994; Gruenwald and Heitz, 1993) .
The CTD has been found to exist in multiple phosphorylation states Lee and Greenleaf, 1991; Payne and Dahmus, 1993; Rice et al., 1994) , suggesting that dierent kinases may differentially phosphorylate the CTD and thus play dierent roles in regulating RNA polymerase II activity. Unfortunately, it is dicult to assess the functional signi®cance of CTD phosphorylation by dierent kinases, as the phosphorylated CTD is not required for in vitro transcriptional assays using highly puri®ed components (Jiang and Gralla, 1994; MaÈ kelaÈ et al., 1995; Serizawa et al., 1993a) . It will thus be necessary to use in vivo assays to determine the functional dierences between the various CTD kinases. In this paper we have examined the dierence in phosphorylation of speci®c sites on the CTD by the closely related kinases cyclin C/CDK8 and cyclin H/CDK7/p36, as well as by cyclin B/CDC2. We have also investigated the ability of small-molecule kinase inhibitors to block CTD phosphorylation by these kinases. Both of these analyses will provide important tools for determining the speci®c function of CTD phosphorylation by these dierent CTD kinases.
Results
Puri®ed cyclin C/CDK8, cyclin H/CDK7/p36 and cyclin B/CDC2 enzymes dierentially phosphorylate recombinant CTD substrates Both cyclin C/CDK8 and cyclin H/CDK7/p36 have been implicated in transcriptional regulation. Although cyclin C/CDK8 is associated with a RNA polymerase II holoenzyme and cyclin H/CDK7/p36 with TFIIH, these kinases share a common substrate, the CTD of RNA polymerase II. To determine whether these kinases might have distinct functions, we were interested to see if they caused identical or dierent phosphorylation patterns on RNA polymerase II.
To determine if these kinases can inherently recognize dierent sites on the CTD, mapping studies Figure 1 Dierential phosphorylation of recombinant CTD substrates by cyclin C/CDK8, cyclin H/CDK7/p36, and cyclin B/ CDC2. (a) Schematic of recombinant CTD substrates, shown by repeat number. The consensus repeats are shown as white boxes, non-consensus repeats with lysine substitutions at position as hatched boxes, and other non-consensus repeats as dark gray boxes. (b) Phosphorylation of GST-CTD1 ± 53, GST-CTD1 ± 29, and GST-CTD30 ± 53 by puri®ed, recombinant cyclin C/CDK8, cyclin H/ CDK7/p36 and cyclin B/CDC2. Reactions were electrophoresed on an 8% SDS-polyacrylamide gel and quanti®ed on a Molecular Dynamics Storm PhosphorImager. The phosphorylation of each substrate relative to phosphorylation of GST-CTD1 ± 53 by each kinase was calculated as mean+s.d. from two independent experiments. Data were normalized against mock reactions using SF9 extract alone Differential CTD phosphorylation by cyclin-dependent kinases P Rickert et al were performed in vitro with puri®ed recombinant enzymes and substrates. Three constructs based on the mouse CTD sequence were created and used to express and purify fusion proteins of glutathione S transferase (GST) with repeats 1 ± 29 (GST ± CTD1 ± 29), repeats 30 ± 53 (GST ± CTD30 ± 53), or repeats 1 ± 53 (GST ± CTD1 ± 53). These recombinant proteins, as represented diagrammatically in Figure 1a , were then used as substrates in kinase assays with puri®ed cyclin C/ CDK8, cyclin H/CDK7/p36, and cyclin B/CDC2. All three kinases were able to phosphorylate GST ± CTD1 ± 53 to a similar extent. Figure 1b shows the level of phosphate incorporated by each substrate relative to that by GST ± CTD1 ± 53 in the presence of each kinase. Cyclin C/CDK8 phosphorylated all three substrates fairly equally. Cyclin H/CDK7/p36 phosphorylated GST ± CTD1 ± 53 and GST ± CTD1 ± 29 to a similar extent, but in contrast to cyclin C/CDK8 displayed a fourfold preference for GST ± CTD30 ± 53 as a substrate. Cyclin B/CDC2 also phosphorylated GST ± CTD30 ± 53 preferentially, and surprisingly was barely able to phosphorylate GST ± CTD1 ± 29 under these experimental conditions. These dierences indicate that these kinases can dierently phosphorylate dierent portions of the CTD sequence.
Both cyclin C/CDK8 and cyclin H/CDK7/p36 phosphorylate Ser-5 in the CTD consensus repeat
Our results suggest that cyclin C/CDK8 and cyclin H/ CDK7/p36 have preferences for speci®c phosphorylation sites within the CTD. To analyse these dierences further, these kinases were examined to determine their speci®city for phosphorylation sites within the CTD consensus repeat sequence. Both of the CDK consensus phosphorylation sites in the CTD repeat, Ser-2 and Ser-5, have been demonstrated to be essential in yeast (West and Corden, 1995) . Furthermore, genetic suppression experiments indicate a functional dierence between these two serines in vivo . To determine which speci®c residues in the consensus sequence are phosphorylated by cyclin C/ CDK8, kinase assays were performed using recombinant CTD fusion proteins. These proteins are fusions of glutathione S-transferase (GST) with between 14 and 16 repeats of either the consensus sequence (WT = YSPTSPS), or with alanine substituted for serine at position two or ®ve (A2 = YAPTSPS, A5 = YSPTAPS). The CTD kinases were immunoprecipitated from CEM cell lysate using speci®c antibodies to cyclin C (a-C pep), cyclin H (a-cyc H) and CDC2 (a-CDC2) as indicated in Figure 2 . An immunoprecipitation using normal rabbit serum (NR) was included as a negative control. Figure 2 shows that cyclin C/CDK8 could only phosphorylate the wild type and A2 fusion proteins, but not the A5 fusion protein, indicating that this kinase speci®cally targets the Ser-5 residue in CTD consensus repeats. As previously demonstrated, cyclin H/CDK7/p36 also phosphorylated only the serine at position 5 in the consensus repeat (Roy et al., 1994) , whilst CDC2 was able to phosphorylate both Ser-2 and Ser-5 (Gebara et al., 1997) . The same result was also seen using puri®ed recombinant cyclin/CDK complexes (C/CDK8 and H/CDK7/p36) as shown in Figure 2 , showing that this speci®city is not altered by the presence of other proteins in the immune complexes.
Cyclin C/CDK8, cyclin H/CDK7/p36, and cyclin B/ CDC2 have dierent speci®cities towards non-consensus CTD repeats
Although both cyclin C/CDK8 and cyclin H/CDK7/ p36 phosphorylate the same residue on the CTD consensus sequence, it was possible that they could dierentially recognize various non-consensus repeats. Analysis of the CTD amino acid sequence reveals that the non-consensus repeats (approximately 60% of the CTD) are clustered near the end of the primary CTD structure, and that most of the substitutions occur at position seven. This position is +2 from the residue speci®cally phosphorylated by both cyclin C/CDK8 and cyclin H/CDK7/p36, suggesting that this could be a major determinant of speci®city for these kinases.
To examine the speci®city of these CTD kinases for these non-consensus repeats, the three most common substitutions at this position were chosen: lysine, threonine, and asparagine. Peptides were synthesized with four repeats of the consensus heptapeptide, either unsubstituted or with K, T, or N substituted for serine at position seven: (YSPTSPX) 4 , where X = S, K, T, or N (Research Genetics). These peptides were then tested as substrates for the CTD kinases cyclin C/CDK8, cyclin H/CDK7/p36, or cyclin B/CDC2. As can be seen Figure 2 Phosphorylation of Ser-5 in the CTD consensus repeat by cyclin C/CDK8 and cyclin H/CDK7/p36. CEM whole cell lysates (*300 mg total protein) were immunoprecipitated with a-C pep, a-cyc H (Santa Cruz) or a-CDC2 antibodies. Normal rabbit sera (NR) was used as a negative control. Recombinant cyclin C/CDK8 and cyclin H/CDK7/p36 were puri®ed from SF9 cells. Kinase reactions were performed with 1 mg of WT (GST-[YSPTSPS] 16 ), A2 (GST-[YAPTSPS] 14 ), A5 (GST-[YSPTAPS] 15 ), or no substrate added. Reactions were electrophoresed on a 10% SDS-polyacrylamide gel which was subsequently Coomassie stained, dried, and autoradiographed Differential CTD phosphorylation by cyclin-dependent kinases P Rickert et al in Figure 3a , cyclin C/CDK8 could phosphorylate the consensus (WT), N-substituted, K-substituted and Tsubstituted peptides all to a similar extent. In contrast, phosphorylation of the K-substituted peptide by cyclin H/CDK7/p36 was at least fourfold greater than the other peptides which were otherwise recognized at comparable levels. Cyclin B/CDC2 displayed the most dramatic substrate preference, phosphorylating the Ksubstituted peptide over 20-fold better than either the consensus (WT), N-substituted, or T-substituted peptides. These results are shown graphically in Figure  3b . The presence of this basic residue in position seven of these CTD repeats has a signi®cant eect on the speci®city of these kinases, strongly suggesting structural dierences in the active sites of these enzymes. The selectivity of other kinases for optimal peptide substrates has been correlated with the known structures of their catalytic sites (Songyang et al., 1994) .
Substrate length dependence of CTD phosphorylation by cyclin C/CDK8 and cyclin H/CDK7/p36
The dierence in phosphorylation of recombinant CTD substrates by these kinases may result from recognition of the primary sequence of the CTD or of a folded conformation. To examine how the secondary structure of the CTD aects its ability to be phosphorylated by these kinases, CTD substrates of varying lengths were analysed. If the kinase recognizes each heptapeptide repeat equally, it should phosphorylate these substrates in proportion to the number of repeats present. If, however, the kinase recognizes some secondary structure present with multiple repeats (Cagas and then it may dierentially phosphorylate longer and shorter substrates.
To analyse the length dependence of CTD phosphorylation, DNA constructs were created for expression and puri®cation of GST-fusion proteins with 4, 6, 8 or 10 repeats of the CTD consensus sequence: GST-(YSPTSPS) 4-10 . These recombinant proteins were then assayed as substrates for puri®ed cyclin C/CDK8 or cyclin H/CDK7/p36. Figure 4a shows that both cyclin C/CDK8 and cyclin H/CDK7/ p36 cause greater incorporation of phosphate onto the longer substrates. However, cyclin C/CDK8 routinely phosphorylated the shorter substrates signi®cantly more eciently than did cyclin H/CDK7/p36. The quanti®cation of these results is shown in Figure 4b . If these kinases phosphorylated each repeat on these substrates equally, with twice as many phosphates on GST-(YSPTSPS) 8 as on GST-(YSPTSPS) 4 , a plot of kinase activity versus number of repeats on this graph would be expected to have a slope of 2. The plot of cyclin C/CDK8 CTD phosphorylation has a slope of 0.99, while the plot of cyclin H/CDK7/p36 phosphorylation has a slope of 2.7. Similar results are obtained with cyclin C/CDK8 and cyclin H/CDK7/p36 immunoprecipitated from cell lysates (data not shown). Cyclin C/CDK8 thus preferentially phosphorylates shorter CTD-like substrates, and cyclin H/CDK7/p36 preferentially phosphorylates longer CTD-like substrates in vitro. Phosphorylation of these substrates by cyclin B/CDC2 indicates that substrate recognition by this kinase is not signi®cantly length-dependent (data not shown). These results suggest that cyclin C/ CDK8 and cyclin H/CDK7/p36 may dierentially recognize secondary structure in the CTD. Cyclin C/CDK8 and cyclin H/CDK7/p36 dierentially phosphorylate an endogenous RNA polymerase II substrate
Our results suggest that there is a speci®city dierence between cyclin C/CDK8 and cyclin H/CDK7/p36 for dierent recombinant CTD substrates. To determine whether this dierence is also observed in vivo, the endogenous RNA polymerase II substrate phosphorylated by cyclin C/CDK8 or cyclin H/CDK7/p36 immune complexes was compared by partial proteolytic mapping. CEM cell lysates were immunoprecipitated with a-cyclin C, a-cyclin H, or normal rabbit antisera. The immunoprecipitations were then incubated with [g-32 P]ATP to allow phosphorylation of associated polypeptides. The kinase reactions were denatured, then reimmunoprecipitated with either an antibody to RNA polymerase II or an isotype control antibody. These reactions were electrophoresed and autoradiographed to visualize the phosphorylated RNA polymerase II band (Figure 5a , lanes 4 and 6), as previously identi®ed in . To proteolytically ®ngerprint these proteins, similar RNA polymerase II bands from a-cyclin C, a-CDK8, a-cyclin H, or a-CDK7 immunoprecipitations were excised from SDS-polyacrylamide gels and digested with various dilutions of Staphylococcus aureus V8 protease (Cleveland et al., 1977) as shown in Figure 5b . Figure 5b shows that the pattern of digested 32 Plabeled fragments obtained from the phosphorylated endogenous RNA polymerase II substrate from cyclin C/CDK8 or cyclin H/CDK7/p36 immunoprecipitates is dierent. Cyclin H/CDK7/p36-associated RNA polymerase II has two phosphorylated digestion products approximately 50 ± 60 kD which are absent from the cyclin C/CDK8-associated RNA polymerase II. In addition, cyclin C/CDK8-associated RNA polymerase II gives rise to more small labeled digestion products (6 ± 15 kD) than are seen with cyclin H/CDK7/p36-associated RNA polymerase II. These dierences in phosphorylated digestion patterns indicate that RNA polymerase II assumes a dierent phosphorylation state in the presence of each kinase. As an internal control, the digestions were performed with phosphorylated RNA polymerase II from cyclin and CDK immunoprecipitates separately. The patterns from each cyclin match those from their respective kinase partner.
The dierent patterns observed are consistent with the inherent speci®city of these kinases for certain phosphorylation sites on the CTD as shown by previous experiments. However we can not rule out the in¯uence of other factors in vivo, such as the existence of pre-existing phosphates on RNA polymerase II, dierent accessibilities of these kinases for this substrate, or maybe even the presence of other proteins (e.g. kinases) present in cyclin C/CDK8 and cyclin H/ CDK7/p36 immune complexes.
Dierential inhibition of cyclin C/CDK8 and cyclin H/ CDK7/p36 by ATP analogs
To study the functional consequences of dierential CTD phosphorylation by the dierent CTD kinases we evaluated a number of chemical kinase inhibitors in search of a selective compound that could speci®cally inhibit one enzyme but not the other. The compounds H7 (1-(5-isoquinolinoylsulfonyl)-3-methylpiperazine), H8 (N-[2-(methylamino)-ethyl]-5-isoquinoline sulfonamide), and DRB (5,6-dichloro-1-b-M-ribofuranosylbenzimidazole) can inhibit transcriptional processes, possibly through their ability to inhibit CTD phosphorylation (Dubois et al., 1994a; Sehgal et al., 1976; Serizawa et al., 1993a) . These ATP analogs have been described to inhibit various CTD kinases, including the TFIIH-associated kinase, cyclin H/ CDK7/p36 (Cisek and Corden, 1991; Payne and Dahmus, 1993; Serizawa et al., 1993b; Stevens and Maupin, 1989; Yankulov et al., 1995) .
To determine whether H7, H8 and DRB could also inhibit cyclin C/CDK8-associated kinase activity, kinase assays were performed with puri®ed recombinant cyclin C/CDK8 or cyclin H/CDK7/p36 in the presence of various concentrations of these inhibitors. The puri®ed kinase was pre-incubated with the inhibitor for 10 min, and then the CTD peptide substrate (YSPTSPS) 4 , [g-32 P]ATP, and non-labeled ATP were added and the reactions were incubated for an additional 30 min. Kinase activity was quanti®ed as shown in Figure 6 , and each IC 50 value and its estimated uncertainty were calculated as the mean+s.d. from three independent experiments (Table  1) . Figure 6 and Table 1 show that H7, H8, and DRB can all inhibit cyclin C/CDK8 kinase activity towards Differential CTD phosphorylation by cyclin-dependent kinases P Rickert et al the CTD peptide. Interestingly, H7 and H8 have dierent speci®cities towards cyclin C/CDK8 and cyclin H/CDK7/p36. H7 preferentially inhibited cyclin C/CDK8 (IC 50 &4 mM versus 40 mM for cyclin H/ CDK7/p36), and H8 preferentially inhibited cyclin H/ CDK7/p36 (IC 50 &6 mM versus 50 mM for cyclin C/ CDK8). DRB, on the other hand, inhibited both cyclin C/CDK8 and cyclin H/CDK7/p36 similarly (IC 50 &20 mM). Similar results were obtained with cyclin C and cyclin H complexes immunoprecipitated from human cell lysates (data not shown). The dierent speci®cities of these inhibitors for these CTD kinases suggests that the enzymes' active sites have dierent conformations. However the dierences are unlikely to be of sucient magnitude to provide speci®c inhibition in an intact cell, so we tested other ATP analogs that have been discovered to be highly speci®c for cyclindependent kinases.
These CDK inhibitors can easily block cell growth and may be useful as potential anti-tumor agents and for biochemical and functional analysis of CDKs (Meijer, 1996) . Two of these inhibitors,¯avopiridol [(+) cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-4H-benzopyran-4-one] (Lo- Figure 5 V8 proteolytic mapping of phosphorylated RNA polymerase II. (a) CEM whole cell lysate (*1.5 mg) was immunoprecipitated with a-C pep, a-cyclin H and normal rabbit (NR) as a negative control and assayed for kinase activity. The immune complex kinase reactions were denatured and reimmunoprecipitated with either an a-RNA polymerase II monoclonal antibody (Promega) or PAb 419 as a negative control. Samples were electrophoresed on a 6% SDS-polyacrylamide gel and visualized by autoradiography. (b) Kinase assays were performed as above with a-C pep, a-CDK8 pep, a-H (Santa Cruz) or a-CDK7 (Santa Cruz) antisera and electrophoresed on a 6% SDS-polyacrylamide gel. The phosphorylated RNA polymerase II from each reaction was excised from the gel and compared by V8 partial proteolytic mapping on an 8 ± 20% gradient SDSpolyacrylamide gel Figure 6 Inhibition of cyclin C/CDK8 (*) and cyclin H/CDK7/p36 (*) kinase activity by H7, H8 and DRB. Recombinant, puri®ed cyclin C/CDK8 and cyclin H/CDK7/p36 enzymes were pre-incubated with the indicated concentration of inhibitor. Kinase reactions were then performed in the presence of the inhibitor using the CTD peptide (YSPTSPS) 4 . Kinase reactions were electrophoresed on 14% SDS-polyacrylamide gels and quanti®ed on a Molecular Dynamics PhosphorImager Differential CTD phosphorylation by cyclin-dependent kinases P Rickert et al siewicz et al., 1994; Meijer, 1996) and olomoucine [2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine], were analysed to determine if they could inhibit cyclin C/CDK8-associated kinase activity. Inhibition assays were performed as described above for the transcriptional inhibitors with cyclin C/CDK8 and cyclin H/ CDK7/p36. As a positive control, cyclin B/CDC2 CTD kinase activity was also monitored in the presence of these inhibitors. As shown in Figure 7¯avopiridol was a potent inhibitor of both cyclin C/CDK8 (IC 50 &20 nM) and cyclin B/CDC2 (IC 50 &10 nM) and, to a lesser extent, cyclin H/CDK7/p36 (IC 50 &100 nM) (see also Table 2 ). This compound has previously been found to speci®cally inhibit CDC2, CDK2 and CDK4 at fairly low concentrations (IC 50 &0.4 mM for cyclin B/CDC2 using histone H1 as a substrate). Interestingly, cyclin B/CDC2 phosphorylation of the CTD peptide was much more sensitive to¯avopiridol than was its phosphorylation of histone H1.
Olomoucine strongly inhibited cyclin H/CDK7/p36 (IC 50 &10 mM) and cyclin B/CDC2 (IC 50 64 mM) but was much less eective towards cyclin C/CDK8 (IC 50 &90 mM) (see Figure 7 and Table 2 ). This inhibitor has been previously described as being highly speci®c for CDC2, CDK2 and CDK5 (IC 50 &7 mM for cyclin B/CDC2 using Histone H1 as a substrate) and can also cause cell cycle arrest at both G1/S and G2/M (Abraham et al., 1995; Glab et al., 1994; Misteli and Warren, 1995; Vesely et al., 1994) . However, an isomer of olomoucine called isoolomoucine [2-(2-hydroxyethylamino)-6-benzylamino-7-methylpurine], which had little inhibitory activity towards cyclin B/CDC2 (IC 50 40.5 mM) or cyclin H/CDK7/p36 (IC 50 41 mM), was able to inhibit cyclin C/CDK8 as well as olomoucine (IC 50 &90 mM). Isoolomoucine has not been previously found to inhibit CDC2, CDK2 or CDK5 (IC 50 4500 mM for cyclin B/CDC2 using histone H1 as a substrate) (Vesely et al., 1994) . All three kinases were resistant to the inhibitor solvent, DMSO, up to a concentration of 1% (v/v), so this isoolomoucine-speci®c inhibition is not due to a solvent eect. Cyclin C, cyclin H and CDC2 complexes immunoprecipitated from human cell lysates are similarly inhibited by these molecules (data not shown).
Whilst evaluation of these small chemical inhibitors suggested that selectivity between the CTD kinases may ultimately be achievable, existing compounds do not present enough speci®city to be useful in evaluating the dierential roles of the CTD kinases.
Discussion
Dierential phosphorylation of the carboxyl-terminal domain (CTD) of RNA polymerase II by dierent CTD kinases may be important for dierential regulation of CTD function. Cyclin C/CDK8 and cyclin H/CDK7/p36 are both CTD kinases, found in distinct complexes associated with the transcriptional machinery (Maldonado et al., 1996; Rickert et al., 1996; Roy et al., 1994; Serizawa et al., 1995; Shiekhattar et al., 1995) . It has been demonstrated here that these kinases can dierentially phosphorylate the CTD of RNA polymerase II, both as an exogenous recombinant substrate and as an endogenous substrate.
Cyclin C/CDK8 and cyclin H/CDK7/p36 both phosphorylate the same residue in the CTD consensus Figure 7 Inhibition of cyclin C/CDK8 (*), cyclin H/CDK7/p36 (*) and cyclin B/CDC2 (x) kinase activity by¯avopiridol, olomoucine, and isoolomoucine. Recombinant, puri®ed cyclin C/CDK8, cyclin H/CDK7/p36, and cyclin B/CDC2 enzymes were pre-incubated with the indicated concentration of inhibitor. Kinase reactions were then performed in the presence of the inhibitor using the CTD peptide (YSPTSPS) 4 . Kinase reactions were electrophoresed on 14% SDS-polyacrylamide gels and quanti®ed on a Molecular Dynamics PhosphorImager -5) . There is a dierence in their ability to phosphorylate CTD substrates of varying lengths, suggesting that these kinases may dierentially recognize secondary structure in the substrate. However, the major dierences seen in phosphorylation of recombinant CTD substrates by these kinases and by cyclin B/ CDC2 may be attributed to their dierent ability to phosphorylate CTD non-consensus sequences with a lysine substituted for serine at position seven, with both cyclin H/CDK7/p36 and cyclin B/CDC2 preferentially recognizing this substituted repeat. The appearance of most of the lysine-substituted non-consensus repeats in the last third of the CTD is consistent with the results observed with the three GST ± CTD fusion proteins. The dierences in phosphorylation of the recombinant CTD substrate are less dramatic than those with the lysine-substituted peptide, presumably due to the presence of non-lysine-substituted repeats, but are still signi®cant. It would be interesting to examine the eects of removing or adding such non-consensus repeats to the CTD in an in vivo assay (Bartolomei et al., 1988) . In addition, analysing the eects of CTD phosphorylation on Plasmodium berghei RNA polymerase II, which has a high number of lysine substitutions at the same position (Giesecke et al., 1991) , may provide insight into the roles of cyclin C/CDK8 and cyclin H/CDK7/p36.
The dierent speci®city of the ATP analogs to inhibit CTD phosphorylation by cyclin-dependent kinases provides further evidence that these kinases may have a dierent conformation in or near their ATP-binding sites. The crystal structure of CDK2 complexed with olomoucine shows that the purine ring of olomoucine binds CDK2 in the same location as ATP, but with the purine ring oriented dierently from that of ATP (Schulze-Gahmen et al., 1995) . Although the purine N7 atom of olomoucine makes various contacts with CDK2, the identical inhibition pro®les of isoolomoucine and olomoucine for cyclin C/CDK8 suggest that neither N7 nor N9, the locations of the dierently substituted methyl groups, makes signi®cant contacts to this kinase. Olomoucine is thus likely to bind cyclin C/CDK8 in a dierent orientation than it does the other CDKs. The dierent structures of these kinase active sites may explain their dierent specificities towards CTD substrates. Furthermore, cyclin H/ CDK7/p36, but not cyclin C/CDK8, can phosphorylate GST ± CDK2 and Histone H1 (Rickert, 1997) , showing a dierent substrate speci®city between these two kinases. The ability of H7, H8, and DRB to inhibit both of these kinases indicates that more selective compounds will need to be identi®ed for further dissection of the functions of CTD kinases in transcription regulation in vivo.
The ability of these cyclin-dependent kinases to cause dierent phosphorylation patterns on the CTD does not require the presence of other proteins or preexisting phosphates to confer speci®city. However, these conditions may modulate these kinases' phosphorylation pattern in vivo. Phosphorylation of the full length CTD construct, GST-CTD1-53, by immunoprecipitated cyclin H/CDK7/p36 and cyclin B/CDC2 was 2 ± 3-fold more ecient than by puri®ed enzymes (data not shown), suggesting that speci®city may be aected by other proteins in the complexes or by posttranslational modi®cations. In addition, the V8 digestion pattern of an endogenous RNA polymerase II substrate appears more complex than the simple pattern produced from a recombinant CTD substrate (data not shown). This suggests that there may be other phosphorylation sites on RNA polymerase II not found in the CTD itself, as is the case with Trypanosoma brucei RNA polymerase II, which becomes phosphorylated despite a lack of heptapeptide repeats (Chapman and Agabian, 1994) .
The experiments presented here demonstrate that cyclin C/CDK8 and cyclin H/CDK7/p36 can differentially phosphorylate their common substrate, the carboxyl-terminal domain of RNA polymerase II. These kinases are found in separate complexes associated with transcriptional proteins, suggesting that they may have dierent roles (Maldonado et al., 1996; Rickert et al., 1996) . These ®ndings are in support of previous genetic evidence that the yeast homologs of cyclin C/CDK8 and cyclin H/CDK7/p36, SRB10/SRB11 and KIN28/CCL1, respectively, have distinct functions (Kuchin et al., 1995; Liao et al., 1995; Simon et al., 1986; Valay et al., 1993) . Together, these results suggest that these kinases play dierent roles in regulating the functions of the CTD and RNA polymerase II.
Materials and methods

Materials
[g-32 P]ATP (4 5000 Ci/mmol) was obtained from Amersham. H7 (Sigma) and H8 (Seikagaku Corporation) were used from 10 mM stock solutions in H 2 O. DRB (Sigma) was used from a 10 mM stock solution in ethanol. Olomoucine and isoolomoucine were both obtained from Calbiochem and used from 25 mM stock solutions in dimethylsulfoxide (DMSO). Flavopiridol was obtained from the National Cancer Institute and was used from a 10 mM stock solution in DMSO. V8 protease was obtained from Worthington. The anti-cyclin C and anti-CDK8 antibodies a-C pep and a-CDK8 pep have been previously described . Cyclin H and CDK7 antibodies were obtained from Santa Cruz Biotechnology, Inc.
Recombinant proteins from Sf9 cells
cDNAs expressing human cyclin C and human CDK8 were cloned into a pVL1393 baculovirus transfer vector (PharMingen). CDK8 was epitope-tagged (EEEEYMPME) at its amino-terminus for anity puri®cation. The vectors were transfected into Ready-Plaque Sf9 cells (Novagen) and recombinant baculovirus was isolated and ampli®ed according to the manufacturer's directions. Cyclin B (GST-fusion protein) and CDC2 (Hemagglutinin (HA)-tagged) baculoviruses were similarly created. Cyclin H (66His-tagged), CDK7 (HA-tagged), and p36 MAT1 baculoviruses were gifts from DO Morgan (University of California, San Francisco). Sf9 cells were infected with these baculoviruses as described (Gruenwald and Heitz, 1993) . For puri®ed enzymes, cells were co-infected with cyclin C and Glu-CDK8 together or His-cyclin H, HA-CDK7, and p36 together. Cells were singly infected with either GST-cyclin B or HA-CDC2.
Cells were harvested and washed in 50 mM HEPES pH 7.0, 150 mM NaCl by centrifuging at 1000 r.p.m. 48C for 5 min. The cells were resuspended in 5 ml E1A lysis buer (50 mM HEPES pH 7.0, 150 mM NaCl, 0.1% NP-40, 5 mg/ml aprotinin, 5 mg/ml leupeptin, 5 mg/ml pepstatin, and 125 mg/ml Pefabloc 1 SC) per gram of cells and rocked at 48C for 30 min. The mixture was then homogenized with 20 strokes in a Dounce homogenizer and centrifuged at 10 000 r.p.m. 48C for 20 min to remove cell debris. Cyclin B and CDC2 lysates were mixed at room temperature for 20 min. The lysates were then puri®ed on a-Glu (Grussenmeyer et al., 1985) or 12CA5 (Field et al., 1988) coupled to protein G Sepharose 1 , or glutathione-agarose as appropriate, eluting with two column volumes of 100 mg/ml antigenic Glu peptide or antigenic hemagglutinin peptide in phosphatebuered saline, or two column volumes of 20 mM reduced glutathione in 50 mM Tris pH 8.0. The peptides were EEEEYMPME (Glu) and YPYDVPDYA (HA) and were obtained from Research Genetics. Puri®ed enzymes were assayed for purity and for activity (Rickert, 1997) .
Construction of GST-CTD fusion proteins
GST-CTD1 ± 53, GST-CTD1 ± 29, and GST-CTD30 ± 53 were derived by PCR from cDNA encoding the mouse CTD, using oligonucleotide primers speci®c for the sequences encoding the repeats indicated. The PCR products were subcloned into pGEX-6P (Pharmacia Biotech) for expression and puri®cation as GST-fusion proteins (Sambrook et al., 1989) . The GST-CTD fusion proteins WT, A2, and A5 were subcloned from constructs described in (West and Corden, 1995) . The GST-(YSPTSPS) n , n=4, 6, 8, or 10, were created as described in (West and Corden, 1995) and were subcloned into a GST vector as described in .
Kinase assays
Kinase assays and reimmunoprecipitations were performed as previously described . For assays using puri®ed enzymes, 0.5 mg of puri®ed enzyme (cyclin C/ CDK8, cyclin H/CDK7/p36, or cyclin B/CDC2) was used. 1 mg of CTD peptides (YSPTSPX) 4 , GST-CTD1 ± 53, GST-CTD1 ± 29, or GST-CTD30 ± 53 was used as a substrate. For the substrate length dependence, 100 pmol of GST-(YSPTSPS) n , n=4, 6, 8, or 10, was added as a substrate. Results were normalised against mock reaction controls.
Inhibition assays
Puri®ed enzymes or immunoprecipitations from cells, prepared as described above or in , were added to kinase buer containing inhibitors at various concentrations to a total volume of 19 ml. This mixture was incubated at 308C for 10 min. Subsequently, a 1 ml reaction mix containing 1 mg of CTD peptide, 2 mCi [g-32 P]ATP, and 20 mM ATP (®nal concentration 1 mM) was added to give a ®nal reaction volume of 20 ml. The reactions were incubated at 308C for 30 min, stopped, and analysed as usual. Kinase activity was quanti®ed using a Molecular Dynamics PhosphorImager and calculated as a percentage of activity in the absence of any inhibitors. Inhibition curves were graphed and ®t using CA-Cricket Graph III 1.5.
Partial proteolytic mapping
For V8 mapping of phosphorylated RNA polymerase II, immunoprecipitation-kinase assays were performed as described previously in triplicate using 1 mg of CEM whole cell lysate per assay. The kinase reactions were electrophoresed on 6% SDS-polyacrylamide gels, which were dried and autoradiographed. The RNA polymerase II bands (identi®ed through co-migration of reimmunoprecipitated RNA polymerase II) were excised and used for partial proteolytic mapping with V8 protease as described previously (Cleveland et al., 1977) .
